Molecular Breast Imaging (MBI), also known as Breast-Specific Gamma Imaging (BSGI), is a procedure that is able to detect breast cancers missed by mammography and ultrasound, particularly in women with dense breasts. The MBI procedure is now available in hundreds of breast centers nationwide and is commonly utilized as a tool along with mammography and ultrasound to help in the diagnosis of breast cancer. Although the radiation dose associated with this procedure is already low enough to be used in select cases, new research is being conducted to find ways to reduce the dose further so that MBI may be used in annual breast cancer screening for high-risk women with dense breast tissue. The latest results from this research were presented at the Chicago International Breast Course in October by Marcela Bohm-Velez, M.D., the principal investigator of an ongoing trial at Weinstein Imaging Associates in Pittsburgh, Pa.

 

VidiStar Cardiology PACS

GE Healthcare announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility. Optison is a contrast agent that may improve the visualization of the left ventricular border — an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. Upon approval, GE Healthcare will provide supply of Optison to the U.S. market from its manufacturing facility in Oslo, becoming the only contrast media manufacturer to supply its own stock for the United States.

Agfa HealthCare previewed version 2 of its Impax Business Intelligence solution to the U.S. market at the 98th annual meeting of the Radiological Society of North America in November 2012.

At the 98th annual meeting of the Radiological Society of North America (RSNA) in November 2012, Siemens Healthcare demonstrated continued commitment to its Agenda 2013 global initiative by previewing several works-in-progress imaging systems.

Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice.

Cloud Storage

Business and technology analyst Ovum has published three “Trends to Watch" reports on cloud computing and reveals that 2013 will see cloud computing continue to grow rapidly.

Mach 7 Technologies unveiled the latest version of its enterprise clinical imaging platform, Keystone Suite, at the 98th annual meeting of the Radiological Society of North America (RSNA) in November 2012.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now